24 ARV-471, a PROTAC Estrogen Receptor (ER) Degrader in Advanced ER+/Human Epidermal Growth Factor Receptor 2 (HER2)– Breast Cancer: Phase 2 Expansion (VERITAC) of a Phase 1/2 Study
Closing Remarks on the Future of Treating HER2+ Metastatic Breast Cancer
Thought leaders in breast oncology share closing remarks about the future management of HER2+ BC with brain metastases with key insights on unmet needs and evolving treatment approaches.
Expert Perspectives on Updates in HER2+ BC Presented at the 2022 ASCO Annual Meeting
Expert panelists discuss insights on HER2+ BC from the 2022 ASCO Annual Meeting including safety updates from DESTINY-BREAST03, data on the potential prognostic value of TILs, and trials on local therapy for oligometastatic disease.
Challenges Associated With Treating Leptomeningeal Disease in HER2+ mBC
A panel of experts examines the challenges associated with treating leptomeningeal metastases in patients with HER2+ mBC including difficulties with using intrathecal chemotherapy and radiation therapy.
Treatment Strategies in Patients with HER2+ BC and Active vs Progressive Brain Metastases
Rita Nanda, MD, reflects on the use of systemic treatment with tucatinib in patients with visceral and CNS disease, and Ryan Jones, MD, discusses the evolving role of concurrent systemic therapy with radiosurgery.
Clinical Case 3: A Patient with HER2+ BC and Brain Metastases Treated with Tucatinib
Highlighting the clinical scenario of a 29-year-old woman with breast cancer, Tiffany Traina, MD, leads a discussion on challenges associated with accurate biomarker testing, tumor heterogeneity, and repeat biopsies.
The Role of the Radiation Oncologist in the Treatment of HER2+ BC and Brain Metastases
Key opinion leaders in the management of breast cancer discuss the role of the radiation oncologist in treating patients with brain metastases.
Selecting and Sequencing Tucatinib and T-DXd in HER2+ BC and Brain Metastases
Centralizing the conversation on trastuzumab deruxtecan, panelists comment on treatment toxicity and factors to consider when sequencing therapies in later lines of treatment.
Clinical Case 2: A Patient with HER2+ BC and Brain Metastases Treated with T-DXd
To discuss treatment options beyond the frontline setting, Erika Hamilton, MD, presents the clinical scenario of a 43-year-old woman with HER2+ mBC who progressed on paclitaxel/trastuzumab/pertuzumab.
Is There a Role for SRS and WBRT for Brain Metastases in HER2+ BC?
Ryan Jones, MD, reflects on factors to consider when selecting stereotactic radiosurgery vs whole-brain radiotherapy including performance status, extracranial control, number of lesions, and CNS progression.
Optimizing Outcomes in Patients with HER2+ BC with Current and Novel Therapies
A panel of experts discusses factors to consider when selecting treatment for patients with HER2+ mBC including brain metastases, quality of life, and treatment resistance.
Selecting the Appropriate Treatment for Patients with HER2+ mBC in Frontline and Beyond
Focusing discussion on the first clinical scenario, panelists examine currently available first- and second-line treatment approaches for HER2+ mBC.
Clinical Case 1: A 41-year-old Patient with HER2+ Metastatic Breast Cancer
Rita Nanda, MD, leads a discussion of the first clinical scenario, a 41-year-old woman with HER2+ metastatic breast cancer who progressed on docetaxel/trastuzumab/pertuzumab.
Overview of HER2+ Metastatic Breast Cancer (mBC)
To begin the program, an expert panel of leaders in the management of HER2+ metastatic breast cancer provides an overview of the disease landscape.
2 Clarke Drive Cranbury, NJ 08512